RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
November 04, 2020 10:30 ET
|
RedHill Biopharma Ltd.
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
April 20, 2020 09:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...